N-(2,2-二乙氧基乙基)吡啶-2-甲胺 | 6957-15-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-(2,2-二乙氧基乙基)吡啶-2-甲胺
• 英文名称: N-(2,2-diethoxyethyl)pyridine-2-methylamine
• 英文别名: 2,2-diethoxy-N-(pyridin-2-ylmethyl)ethanamine；2-Pyridyl-methylamino-acetaldehyd-acetal
• CAS: 6957-15-9
• 化学式: C₁₂H₂₀N₂O₂
• mdl: MFCD00086205
• 分子量: 224.303
• InChiKey: INTMTQABLHWPSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.583
• 拓扑面积：
  43.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  potassium thioacyanate 、 N-(2,2-二乙氧基乙基)吡啶-2-甲胺 在 盐酸 作用下， 以 水 为溶剂， 反应 1.0h， 以51%的产率得到1-(2-吡啶基甲基)-1,3-二氢-2H-咪唑-2-硫酮
  参考文献：
  名称：

  Inhibitors of dopamine .beta.-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones

  摘要：

  The 1-benzylimidazole-2-thione moiety has been previously shown by Kruse et al. to be broadly associated with dopamine beta-hydroxylase (DBH) inhibitory activity both in vitro and in vivo in spontaneously hypertensive rats (SHR). An extension of structure-activity studies to 1-(pyridylmethyl)- and 1-(oxypyridylmethyl)imidazole-2-thiones is reported here in an attempt to exploit the pH differential that exists across the chromaffin vesicle membrane. We hypothesized that the weakly basic pyridyl compounds would diffuse into the acidic vesicles in their neutral forms where protonation and concentration would occur to enhance their in vivo effectiveness as inhibitors. To test this hypothesis, isomeric 2-, 3- and 4-(1-pyridylmethyl)imidazole-2-thiones were synthesized from the appropriate pyridinecarboxaldehydes by reductive alkylation of aminoacetaldehyde dialkyl acetal followed by imidazole-2-thione formation using acidic potassium thiocyanate. Related oxypyridyl compounds were synthesized by first preparing the appropriate aldehyde intermediate followed by conversion to the imidazole-2-thione by the same procedure. The unsubstituted pyridylmethyl compounds showed modest DBH inhibition in vitro but, consistent with a transport-mediated increase in observed potency, showed significant effects in vivo to increase the vascular ratio of dopamine to norepinephrine and to lower blood pressure.

  DOI：

  10.1021/jm00391a008
• 作为产物：
  描述：

  吡啶-2-甲醛 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 N-(2,2-二乙氧基乙基)吡啶-2-甲胺
  参考文献：
  名称：

  Inhibitors of dopamine .beta.-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones

  摘要：

  The 1-benzylimidazole-2-thione moiety has been previously shown by Kruse et al. to be broadly associated with dopamine beta-hydroxylase (DBH) inhibitory activity both in vitro and in vivo in spontaneously hypertensive rats (SHR). An extension of structure-activity studies to 1-(pyridylmethyl)- and 1-(oxypyridylmethyl)imidazole-2-thiones is reported here in an attempt to exploit the pH differential that exists across the chromaffin vesicle membrane. We hypothesized that the weakly basic pyridyl compounds would diffuse into the acidic vesicles in their neutral forms where protonation and concentration would occur to enhance their in vivo effectiveness as inhibitors. To test this hypothesis, isomeric 2-, 3- and 4-(1-pyridylmethyl)imidazole-2-thiones were synthesized from the appropriate pyridinecarboxaldehydes by reductive alkylation of aminoacetaldehyde dialkyl acetal followed by imidazole-2-thione formation using acidic potassium thiocyanate. Related oxypyridyl compounds were synthesized by first preparing the appropriate aldehyde intermediate followed by conversion to the imidazole-2-thione by the same procedure. The unsubstituted pyridylmethyl compounds showed modest DBH inhibition in vitro but, consistent with a transport-mediated increase in observed potency, showed significant effects in vivo to increase the vascular ratio of dopamine to norepinephrine and to lower blood pressure.

  DOI：

  10.1021/jm00391a008

文献信息

• ALPHA HELIX MIMETICS AND METHODS RELATING THERETO
  申请人：Odagami Takenao

  公开号：US20120088770A1

  公开（公告）日：2012-04-12

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  本文披露了代表公式(I)的α-螺旋类似物结构和化合物，其中一般公式和每个符号的定义如规范所定义，以及与之相关的化学库和方法。此外，还披露了这些化合物在治疗医疗状况（例如癌症疾病、纤维化疾病）方面的应用，以及包括类似物的制药组合物。
• ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER
  申请人：Kouji Hiroyuki

  公开号：US20110263607A1

  公开（公告）日：2011-10-27

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  本发明涉及Alpha-螺旋拟态结构和化合物，其由公式（I）表示，其中一般公式和每个符号的定义如规范中所定义，涉及该化合物的一种化合物以及涉及该化合物的方法。还公开了这些化合物在治疗医疗状况（例如癌症疾病、纤维化疾病）中的应用，以及包含这些拟态物质的制药组合物。
• Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
  申请人：Kouji Hiroyuki

  公开号：US08691819B2

  公开（公告）日：2014-04-08

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  本文披露了代表公式（I）的α-螺旋拟态结构和化合物，其中一般公式和每个符号的定义如规范中所定义，以及相关的化合物和方法。进一步披露了这些化合物在治疗医学状况，例如癌症疾病、纤维化疾病以及包含拟态体的制药组合物的应用。
• ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS
  申请人：PRISM BioLab Corporation

  公开号：US20140221657A1

  公开（公告）日：2014-08-07

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  本发明公开了代表公式（I）的α-螺旋类似物结构和化合物，其中一般公式和每个符号的定义如规范中所定义，涉及该化合物的方法以及涉及该方法的应用，用于治疗医学疾病，例如癌症疾病，纤维化疾病，以及包含类似物的制药组合物。
• [EN] ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER<br/>[FR] MIMÉTIQUES D'HÉLICE ALPHA DANS LE TRAITEMENT DU CANCER
  申请人：PRISM BIOLAB CORP

  公开号：WO2010044485A1

  公开（公告）日：2010-04-22

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  本发明公开了代表公式(I)的α-螺旋拟态结构和化合物，其中一般公式和每个符号的定义如规范所定义，涉及该化合物的化合物和涉及该化合物的方法。还公开了这些化合物在治疗医学疾病（例如癌症，纤维化疾病）中的应用以及包含这些拟态体的制药组合物。